Kane Biotech Inc., a biotechnology company specializing in advanced wound care solutions, has officially announced the resumption of its commercial activities across both the United States and Canada. This strategic move comes alongside the appointment of two experienced industry leaders to spearhead business development efforts throughout North America, marking a significant revitalization of the company's market presence.
Commercial Restart in Key Markets
In the United States, Kane Biotech has established non-exclusive distribution and sales agreements with Medstream Healthcare Solutions, LLC, based in Dorval, Florida, and Patient Care Medical located in Austin, Texas. Initial shipments of the revyve Antimicrobial Wound Gel product line are anticipated to commence in the near term, signaling a renewed push into the American healthcare market.
Simultaneously, in Canada, the company has reactivated its commercial operations by converting its existing distribution agreement with Best Buy Medical Canada into a non-exclusive arrangement. This transition is complemented by targeted sales initiatives and sampling programs designed to increase product visibility and adoption among healthcare providers.
While current sales volumes in both countries remain modest, these developments represent a meaningful restart of Kane Biotech's commercial engine, laying the groundwork for future growth and market penetration.
Strategic Leadership Appointments
To support this next phase of expansion, Kane Biotech has appointed two Vice Presidents of Business Development, each bringing extensive expertise to their respective regions.
Sherida (Kay) Watkins Weaver
Kay Watkins Weaver assumes the role of Vice President of Business Development for the United States. With over two decades of experience in wound care commercialization, her background includes leadership positions at Omeza and Relevate Health. She has demonstrated proficiency in developing market access strategies, managing reimbursement processes, and driving adoption across various healthcare settings, including health systems, long-term care facilities, and home health markets.
Patti Burke-Martin
Patti Burke-Martin has been appointed Vice President of Business Development for Canada. Recognized as a national leader in wound care, she has held senior roles at EO2 Concepts, Coloplast, and ConvaTec. Her proven track record includes building high-performing teams and successfully promoting the adoption of advanced wound care technologies throughout the Canadian healthcare landscape.
Executive Commentary
Dr. Robert Huizinga, Interim CEO of Kane Biotech, emphasized the company's commitment to a disciplined market approach. "We are executing on our commitment to reset Kane Biotech using a disciplined market approach," he stated. "We will continue to generate scientific credibility, clinical validation, and with that, the commercial infrastructure."
Regarding the new appointments, Dr. Huizinga added, "Kay and Patti bring deep expertise and trusted relationships in their respective markets. Their leadership will be instrumental as we expand our distribution network and support the growing adoption of revyve."
About Kane Biotech and revyve Products
Kane Biotech Inc. is focused on commercializing and developing innovative wound care treatments that disrupt biofilms and enhance healing outcomes. Biofilms are a primary contributor to antibiotic resistance in wounds, leading to severe clinical consequences and significant healthcare costs. The revyve product line addresses both biofilms and wound bacteria, offering a dual-action solution for effective wound management.
The revyve Antimicrobial Wound Gel and revyve Antimicrobial Wound Gel Spray have received U.S. FDA 510(k) clearance, while the revyve Antimicrobial Wound Gel is also approved by Health Canada. These regulatory milestones underscore the products' safety and efficacy, positioning them as valuable tools in modern wound care protocols.
